Double-digit revenue growth
Three new contracts signed in September, including first wearables contract
IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today provides the following pre-close trading update ahead of its preliminary results for the year ended 30 September 2017.
The Company is pleased to report revenue for the year of £3.7 million (2016: £3.1 million). The £0.6 million increase, or c.20% growth over the prior year, reflects traction in the Company’s commercially led organic growth strategy focused on the global biopharma market. As a result the Company expects to be ahead of expectations for EBITDA and operating losses for the current financial year.Click edit button to change this text.
IXICO today announces that it has signed a new contract, with a top 15 global pharmaceutical company, utilising wrist worn activity sensors (‘wearable biosensors’) in a Phase II clinical trial for a neurological disorder. This is IXICO’s [...]
IXICO, the digital technologies company serving neuroscience, today announces that it has signed a new contract with a customer for its technology enabled imaging services. The contract value is US$690k over a two and a half year [...]
IXICO to provide specialist MR and PET imaging services in Phase II Huntington’s disease clinical trial
IXICO today announces that it has signed a new contract with a North American based biopharmaceutical company. The contract value is £1.2m over a three year term. IXICO will provide its technology enabled imaging services in [...]
IXICO announces an expansion of its pilot of the Assessa® PML platform which includes Biogen, a leading company in Multiple Sclerosis (“MS”), and expert reading institutions. The Assessa® PML digital platform is being piloted in five [...]
IXICO is today holding an Expert Symposium on the impact and future of imaging and digital biomarkers in Alzheimer’s disease. The symposium is set to coincide with the Alzheimer’s Association International Conference (AAIC) in London, UK. [...]
IXICO today announces that it has signed a new contract for specialist imaging clinical trial services. The contract is for a Phase II clinical trial of patients with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease [...]